ArticleMolecular therapy. Nucleic acids2019
miR-582-3p and miR-582-5p Suppress Prostate Cancer Metastasis to Bone by Repressing TGF-β Signaling.
Article in Molecular therapy. Nucleic acids, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data.British journal of cancer · 2022Pooled it
- Modulation of the nutritional, metabolomic and microRNA profile of colostrum and piglet performance via a high-energy, high-lysine transition diet in sows.Journal of animal science and biotechnology · 2026Article
- DCST1-AS1 promotes renal cell carcinoma progression via regulating the miR-582-5p/HMGB2 axis.Journal of translational medicine · 2025Article
- Epigenetic modifications of the PHOX2A and CDH2 genes expression- new insights into the pathogenesis of multiple myeloma.BMC cancer · 2025Article
- The multifaceted roles of ribosomal P complex in cancer.World journal of surgical oncology · 2025Review
- A Brief Review of MicroRNA Profiling in Human Prostate Cancer Tissues and Plasma.Biomolecules · 2025Review
- Biomarkers in Localized Prostate Cancer: From Diagnosis to Treatment.International journal of molecular sciences · 2025Review
- Bone metastases of prostate cancer: Molecular mechanisms, targeted diagnosis and targeted therapy (Review).Oncology reports · 2025Review
- Hsa_circ_0125356 promotes gemcitabine resistance by modulating WNT canonical and non-canonical pathways via miR-582-5p/FGF9 axis in non-small cell lung cancer.Molecular cancer · 2025Article
- Mechanistic studies ofFrontiers in oncology · 2025Article
- NEAT1 promotes the progression of prostate cancer by targeting the miR-582-5p/EZH2 regulatory axis.Cytotechnology · 2024Article
- MicroRNA-582-5p inhibits the progression of gastric cancer cells and their resistance to oxaliplatin by suppressing ATG7 expression.Frontiers in oncology · 2024Article
- Critical roles of lncRNA-mediated autophagy in urologic malignancies.Frontiers in pharmacology · 2024Review
- hsa-miR-582-3p in umbilical cord blood is negatively associated with maternal exposure to childhood maltreatment.Epigenomics · 2024Article
- The regulatory process and practical significance of non-coding RNA in the dissemination of prostate cancer to the skeletal system.Frontiers in oncology · 2024Review
- Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region.Future science OA · 2023Article
- Review
- Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancer.Journal of cancer research and clinical oncology · 2023Article
- Emerging role of transforming growth factor-β-regulated long non-coding RNAs in prostate cancer pathogenesis.Cancer pathogenesis and therapy · 2023Review
- MicroRNA-345-3p is a potential biomarker and ameliorates rheumatoid arthritis by reducing the release of proinflammatory cytokines.Journal of orthopaedic surgery and research · 2023Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A number of studies have reported that aberrant expression of microRNAs (miRNAs) closely correlates with the bone metastasis of prostate cancer (PCa). However, clinical significance and functional roles of both strands of a single miRNA in bone metastasis of PCa remain undefined. Here, we reported that miR-582-3p and miR-582-5p expression were simultaneously reduced in bone metastatic PCa tissues compared with non-bone metastatic PCa tissues. Downexpression of miR-582-3p and miR-582-5p strongly and positively correlated with advanced clinicopathological characteristics and shorter bone metastasis-free survival in PCa patients. Upregulating miR-582-3p and miR-582-5p inhibited invasion and migration abilities of PCa cells in vitro, as well as repressed bone metastasis in vivo. Our results further revealed that miR-582-3p and miR-582-5p attenuated bone metastasis of PCa via inhibiting transforming growth factor β (TGF-β) signaling by simultaneously targeting several components of TGF-β signaling, including SMAD2, SMAD4, TGF-β receptor I (TGFBRI), and TGFBRII. Moreover, deletion contributes to miR-582-3p and miR-582-5p downexpression in PCa tissues. Finally, clinical negative correlations of miR-582-3p and miR-582-5p with SMAD2, SMAD4, TGFBRI, and TGFBRII were demonstrated in PCa tissues. Thus, our findings explore a novel tumor-suppressive miRNA with its both strands implicated in bone metastasis of PCa, suggesting its potential therapeutic value in treatment of PCa bone metastasis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.